197 related articles for article (PubMed ID: 15231389)
1. Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors.
Everett RS; Evans HK; Hodges BL; Ding EY; Serra DM; Amalfitano A
Virology; 2004 Jul; 325(1):96-105. PubMed ID: 15231389
[TBL] [Abstract][Full Text] [Related]
2. TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression.
Sung RS; Qin L; Bromberg JS
Mol Ther; 2001 May; 3(5 Pt 1):757-67. PubMed ID: 11356080
[TBL] [Abstract][Full Text] [Related]
3. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
4. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
5. Sustained expression of human apo A-I following adenoviral gene transfer in mice.
De Geest B; Van Linthout S; Collen D
Gene Ther; 2001 Jan; 8(2):121-7. PubMed ID: 11313781
[TBL] [Abstract][Full Text] [Related]
6. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
7. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.
Yew NS; Przybylska M; Ziegler RJ; Liu D; Cheng SH
Mol Ther; 2001 Jul; 4(1):75-82. PubMed ID: 11472109
[TBL] [Abstract][Full Text] [Related]
8. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
[TBL] [Abstract][Full Text] [Related]
9. Long-term retinal transgene expression with FIV versus adenoviral vectors.
Loewen N; Leske DA; Cameron JD; Chen Y; Whitwam T; Simari RD; Teo WL; Fautsch MP; Poeschla EM; Holmes JM
Mol Vis; 2004 Apr; 10():272-80. PubMed ID: 15094709
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.
Michou AI; Santoro L; Christ M; Julliard V; Pavirani A; Mehtali M
Gene Ther; 1997 May; 4(5):473-82. PubMed ID: 9274725
[TBL] [Abstract][Full Text] [Related]
11. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.
Muruve DA; Cotter MJ; Zaiss AK; White LR; Liu Q; Chan T; Clark SA; Ross PJ; Meulenbroek RA; Maelandsmo GM; Parks RJ
J Virol; 2004 Jun; 78(11):5966-72. PubMed ID: 15140994
[TBL] [Abstract][Full Text] [Related]
12. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
13. Insertion of CTCF-binding sites into a first-generation adenovirus vector reduces the innate inflammatory response and prolongs transgene expression.
Schaack J; Qiao L; Walkiewicz MP; Stonehouse M; Engel DA; Vazquez-Torres A; Nordeen SK; Shao J; Moorhead JW
Virology; 2011 Mar; 412(1):136-45. PubMed ID: 21272906
[TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral vector expressing ICP47 inhibits adenovirus-specific cytotoxic T lymphocytes in nonhuman primates.
Scaria A; Sullivan JA; St George JA; Kaplan JM; Lukason MJ; Morris JE; Plog M; Nicolette C; Gregory RJ; Wadsworth SC
Mol Ther; 2000 Nov; 2(5):505-14. PubMed ID: 11082324
[TBL] [Abstract][Full Text] [Related]
17. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo.
Schowalter DB; Tubb JC; Liu M; Wilson CB; Kay MA
Gene Ther; 1997 Apr; 4(4):351-60. PubMed ID: 9176522
[TBL] [Abstract][Full Text] [Related]
18. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains.
Barr D; Tubb J; Ferguson D; Scaria A; Lieber A; Wilson C; Perkins J; Kay MA
Gene Ther; 1995 Mar; 2(2):151-5. PubMed ID: 7719932
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
20. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]